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Purpose: Pantoea species are pigmented, Gram-negative rods belonging to the Enterobacterales order. They are
considered rare, opportunistic pathogens and are mostly implicated in nosocomial outbreaks affecting neonates and
immunocompromised patients. The aim of this study was to describe the prevalence and antibiotic susceptibility of
Pantoea species during a 12-year period. Materials and methods: This retrospective study was carried out using
microbiological data collected between January 1, 2006 and December 31, 2017. Patients’ data such as age, sex,
inpatient/outpatient status, and empiric antibiotic therapy were also collected. Antimicrobial susceptibility testing was
performed using E-tests; the interpretation was based on European Committee on Antimicrobial Susceptibility
Testing breakpoints for Enterobacterales. Results: Seventy individual Pantoea spp. isolates were identiﬁed; the most
frequently isolated species was Pantoea agglomerans. Most isolates were susceptible to relevant antibiotics. In 61 out
of 68 patients, ampicillin was the empirically administered antibiotic. The highest levels of resistance were to
amoxicillin–clavulanic acid and ampicillin. No extended spectrum beta-lactamase-positive isolate was detected.
Conclusions: There is a scarcity of data available on the susceptibility patterns of Pantoea species, but our results
correspond to what we could ﬁnd in the literature. The development of multidrug-resistant (MDR) Gram-negative
bacteria is a grave concern, and the development of MDR Pantoea spp. may be expected in the future.
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INTRODUCTION
Pantoea species are pigmented, facultative anaerobic Gram-
negative rods belonging to the Enterobacterales order and
frequently isolated from natural environments (e.g., plants,
soil, and water) [1, 2]. Pantoea agglomerans (previously
known as Erwinia herbicola [1964] and Enterobacter
agglomerans [1972]) is the most frequently isolated mem-
ber of the genus in the context of human infections [3]. It is
generally considered a rare, opportunistic pathogen with low
virulence, mainly implicated in nosocomial outbreaks
affecting neonates and immunocompromised patients
[4, 5]. Most of the affected patients in the literature had
severe underlying illnesses (hematological malignancies or
solid tumours, manifest AIDS); however, infections associ-
ated with penetrative trauma, contaminated intravascular
catheters and ﬂuids (dialysis and intravenous anesthesia),
and agricultural occupation have also been reported
[1, 4, 6, 7]. In addition, associations of P. agglomerans
bacteremia with antacid/proton pump inhibitor use (corre-
sponding to a decreased protective effect of gastric acid) and
gastrointestinal mucosal injury have been described, which
may be attributable to the abundance of P. agglomerans on
fruits or vegetables [4, 8].
The epidemiology and resistance trends of bacterial
pathogens vary greatly by the proﬁle of the healthcare
institution and geographical region; therefore, the assess-
ment of local data is essential to evaluate trends over time
and to reﬂect on international data [9, 10]. The spectrum of
veriﬁed (i.e., clinically signiﬁcant) bacterial pathogens
has signiﬁcantly broadened in recent years, due to the
introduction of matrix-assisted laser desorption/ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS) and
16S rRNA sequencing in the routine diagnostic workﬂow
of microbiology laboratories [11]. The aim of this study
was to describe the prevalence and antibiotic susceptibility
patterns of Pantoea species isolated at a tertiary-care
teaching hospital in Hungary during a 12-year period
(2006–2017).
MATERIALS AND METHODS
Study design and data collection
The present retrospective study was based on microbiolog-
ical data we collected between January 1, 2006 and
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December 31, 2017 at the Institute of Clinical Microbiology
(University of Szeged), the principal clinical microbiology
laboratory of the Albert Szent-Györgyi Clinical Center in
Szeged, Hungary. The Clinical Center has a bed capacity of
1,820 beds and annually serves more than 400,000 patients
in the region, according to the data of the Hungarian
National Health Insurance Fund (NEAK) [12]. Data were
collected for samples positive (105 or more CFU) for
Pantoea species using the Institute’s Laboratory Informa-
tion System. Only the ﬁrst isolate per patient was included
in the study; however, isolates with different antibiotic-
susceptibility patterns were considered as different
individual isolates [11]. Data on affected patients were
also collected, limited to demographic characteristics
(age, sex, and inpatient/outpatient status), indication for
sample submission, and the administered empiric antibi-
otic therapy [13].
Microbiological identiﬁcation
Sample processing in our Institute was carried out accord-
ing to guidelines for routine clinical bacteriology, which
have been previously described [13]. Between 2006 and
2012, the BD Bactec (Beckton Dickinson, Franklin Lakes,
NJ, USA) detection system was employed in our Institute
for the incubation of blood-culture bottles, while from
2013 onward, the BacT/ALERT 3D (bioMérieux, Marcy-
l’Étoile, France) detection system was used [14]. Blood-
culture bottles were incubated for 5 days (21 days, if
endocarditis was suspected) in the aforementioned
detection systems. All culture media were incubated
at 37 °C for 24–48 hr in a 5% CO2 atmosphere, 5%
sheep-blood agar, chocolate agar, and eosin methylene
blue agar. Between 2006 and 2012, presumptive
phenotypic (biochemical reaction-based) methods and
VITEK 2 ID (bioMérieux, Marcy-l’Étoile) were used for
bacterial identiﬁcation, while after 2013, this was com-
plemented by MALDI-TOF MS (Bruker Daltonik Gmbh,
Germany). The methodology of sample preparation for
MALDI-TOF MS measurements has been described
elsewhere [14].
Antibiotic susceptibility testing (AST)
Antimicrobial susceptibility testing (AST) was performed
for ampicillin, amoxicillin–clavulanic acid, chloram-
phenicol, ciproﬂoxacin, ceftriaxone, doxycycline, gentami-
cin, amikacin, meropenem, piperacillin-tazobactam, and
sulfamethoxazole–trimethoprim, using E-test (Lioﬁlchem,
Abruzzo, Italy) on Mueller–Hinton agar plates. Interpreta-
tion of the results was based on European Committee
on Antimicrobial Susceptibility Testing (EUCAST)
breakpoints (http://www.eucast.org) for Enterobacterales.
Staphylococcus aureus ATCC 29213, Enterococcus faeca-
lis ATCC 29212, Proteus mirabilis ATCC 35659, Escher-
ichia coli ATCC 25922, and Pseudomonas aeruginosa
ATCC 27853 were used as quality-control strains. During
data analysis, intermediate results were grouped and
resistance was reported. Since 2011, if extended-spectrum
beta-lactamase (ESBL) production was suspected, detection
was carried out based on EUCAST recommendations
(http://www.eucast.org/resistance_mechanisms/) using the
AmpC-ESBL Detection Set (MAST Diagnostica GmbH,
Reinfeld, Germany) [13].
Statistical analysis
Data consolidation and descriptive statistical analysis
(including means or medians with ranges and percentages
to characterize data) were performed using Microsoft Excel
2013 (Microsoft Corp., Redmond, WA, USA).
RESULTS
Demographic characteristics and sample types
The median age of affected patients was 40 years (range:
0.7–86 years) with a female-to-male ratio of 0.84 (45.59%
female). The detailed age distribution of affected patients
was the following: 0–17 years, n = 10; 18–39 years, n =
18; 40–64 years n = 20; and over 65 years, n = 18. Inpa-
tients were affected around 1.5 times more frequently than
outpatients (n = 41 vs. n = 27, respectively). Most of the
isolates (n = 14) originated from blood cultures, abscesses
(n = 9), and surgical samples (n = 7), followed by lower
respiratory tract samples (trachea, bronchoalveolar lavage,
and sputum), wound samples, and vaginal swabs (n = 6),
gastric juice aspirates (n = 4), catheterized urine and cen-
tral venous catheters (n = 3), urethral swabs, conjunctiva
samples, high cervical swabs, inner ear samples, ejaculates,
and nasal swabs (n = 2 each). In most cases, the reported
empiric therapy was ampicillin (n = 61), followed by
piperacillin/tazobactam (n = 2), amoxicillin/clavulanic ac-
id, cefotaxime, cefuroxime, ceftazidime, and gentamicin
(n = 1 each).
Species distribution and susceptibility of Pantoea isolates
Seventy individual Pantoea spp. isolates were identiﬁed
during the 12-year period. The most frequently isolated
species was P. agglomerans (n= 63), whereas other Pan-
toea species (P. calida: n= 3; P. septica, P. cypripedii,
P. gaviniae, and P. anantis: n= 1 each) were in a minority,
and the identiﬁcation of these isolates was after the
introduction of MALDI-TOF MS (2013). All the isolates
(n= 70) were susceptible to amikacin and meropenem.
In addition, the overwhelming majority was susceptible to
chloramphenicol, doxycycline, and gentamicin (n= 68),
sulfamethoxazole–trimethoprim (n= 66), ceftriaxone (n= 64),
and piperacillin–tazobactam (n= 62). The highest levels of
resistance were recorded to amoxicillin–clavulanic acid (n= 28
were susceptible) and ampicillin (n= 12 were susceptible). No
ESBL-positive isolate was detected.
DISCUSSION
There is a scarcity of data available in the literature on the
susceptibility patterns of Pantoea species, so additional
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data are necessary to provide a comprehensive picture of
resistance trends. This picture would help in choosing an
antimicrobial therapy and, ultimately, in preventing
mortality from infections with Pantoea species [1–3]. In
the Southern Great Plain of Hungary, most of the isolates
were susceptible to the relevant antibiotics for treatment of
Gram-negative infections. Aminopenicillins and amoxi-
cillin–clavulanic acid were exceptions, for which n = 28
and n = 12 isolates were susceptible, respectively; this is
clinically relevant information, as ampicillin was the
most frequently administered antibiotic for the affected
patients. Our results correspond to the ﬁndings of Cheng
et al. (ampicillin susceptibility: 56%, cefazolin suscepti-
bility: 61%, other antibiotics: 100%), Cruz et al.
(ampicillin susceptibility: 47.2%, cefazolin susceptibility:
62.3%, second-generation cephalosporins: 92.5%, other
antibiotics: 100%), and other case studies reporting on
Pantoea spp. infections [2–6, 8]. In the study of Mardaneh
and Dallal [15], 12.5% of isolates were susceptible to
ampicillin, 62.5% were susceptible to meropenem and
amikacin, 75% were susceptible to gentamicin and piper-
acillin–tazobactam, and 100% were susceptible to colistin
and tigecycline. In contrast, Büyükcam et al. [7] reported
three multidrug-resistant (MDR) P. agglomerans strains
in children, all of which were resistant to third-generation
cephalosporins, carbapenems, ciproﬂoxacin, and amino-
glycosides; the infections proved to be fatal in the affected
patients. The development of MDR Gram-negative bacte-
ria (particularly in the Enterobacterales order) is a grave
concern in current clinical practice, and the development
of Pantoea spp. resistant to several antibiotics may be
expected in the future.
CONCLUSIONS
The aim of this study was to report the epidemiological
characteristics and susceptibility patterns of Pantoea spe-
cies in Hungary, over a long period of time (12 years). At
the time of submission, there was no report in the literature
describing the prevalence of Pantoea in Hungary. Clinical
microbiology laboratories have pivotal roles in perform-
ing species-level identiﬁcations and in aiding physicians
in the appropriate choice of empiric antibiotic therapy.
A few drawbacks of this study need to be addressed.
Medical records of the patients were not accessed; thus,
the medical history and symptomatology of these patients
were unknown. During the 12-year study period (between
2012 and 2013), the incubation system and the bacterio-
logical identiﬁcation methods were changed. In addition,
several revisions of the EUCAST recommendations have
been published. Finally, the resistance determinants of
the strains described were not further assayed using poly-
merase chain reaction or sequencing technology. These
factors may have distorted some of the results. For
future reports, the aforementioned limitations could be
addressed, especially the association of Pantoea isolation
with clinical data/symptomatology (through the obtain-
ment of patient data) and the use of molecular characteri-
zation or whole-genome sequencing (WGS) to character-
ize resistance determinants.
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